伊立替康联合洛铂治疗复发广泛期小细胞肺癌临床观察  

Clinical observation of irinotecan plus lobaplatin in treatment of recurrent small cell lung cancer

作　　者：黄海真 张传江 

机构地区：[1]山东菏泽曹县县立医院,山东菏泽274000

出　　处：《世界最新医学信息文摘》2013年第15期44-45,共2页World Latest Medicine Information Electronic Version

摘　　要：目的探讨伊立替康联合洛铂治疗复发广泛期小细胞肺癌的临床疗效及不良反应。方法收集我院自2006年5月至2009年1月间收治的确诊为复发广泛期小细胞肺癌的患者的临床资料，共计45例，采用依立替康200mg／m0，洛铂35mg／m。，21d为一个周期，在治疗2周期后进行疗效评价，并观察不良反应情况。结果完全缓解（CR）1例。部分缓解（PR）16例，疾病稳定（sD）9例，疾病进展（PD）21例，疾病缓解率（ORR）37．8％，疾病控制率（DCR）57．8％，中位无进展生存期（PSF）4．8月，中位生存期（OS）8．4月，主要的不良反应为血液学毒性及消化道反应。结论伊立替康联合洛铂可以作为小细胞肺癌的二线治疗方案，具有较好的疗效，不良反应尚可耐受。Objective To investigate the clinical efficacy and adverse reactions of irinotecan plus lobaplatin in treatment of recurrent small cell lung cancer. Methods collected in our hospital from 2006 May to 2009 January were diagnosed as clinical recurrence of extensive stage small cell lung cancer patients, a total of 45 patients with 200mg/m2, irinotecan, platinum 35mg/ m2, 2id is a cycle, the therapeutic effect was evaluated in 2 cycles after treatment, and observe the adverse reactions. Results the complete response （CR） in 1 cases, partial remission （PR） 16 cases, stable disease （SD） in 9 cases, progression of disease （PD） in 21 cases, remission rate was 37.8% （ORR）, disease control rate （DCR） of 57.8%, the median progression free survival （PSF） was 4：8 months, median survival （OS） was 8.4 months, the major adverse reactions were hematologic toxicity and gastrointestinal reaction. Conclusion the second line treatment of irinotecan combined with platinum can be as small cell lung cancer, has good curative effect, adverse reaction was tolerable.

关 键 词：伊立替康 洛铂 小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]